Search Results

TC BioPharm plc announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,750,000 of the Company’s American Depositary Shares originally issued in December 2023 with an exercise price of £1.5814 per ADS and a term of five years.

TC BioPharm PLC announced the execution of a non-binding letter of intent to acquire a privately-held biotechnology company pursuing the development of innovative Chimeric Antigen Receptor T-cell therapies for the treatment of refractory cancers and solid tumors.

TC BioPharm today announced its participation at the upcoming Sequire Investor Summit 2024 scheduled for January 23-25, 2024.

TC BioPharm today announced the pricing of a public offering of 1,750,000 of its American Depositary Shares.

TC BioPharm PLC announced that CEO, Bryan Kobel and Process Development Manager, Dr. Lauren Bor will be featured “Expert Speakers” at the 7th 7th CAR-TCR Summit Europe, February 27-29th in London, UK.

TC BioPharm today announced the closing of its previously announced public offering of 1,750,000 of its American Depositary Shares.

TC BioPharm PLC a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, announced that on January 2, 2024, the Company received a written notice from The Nasdaq Stock Market.

TC BioPharm today announced that the Company is undertaking a series of initiatives to reduce costs and drive efficiency in order to reduce cash burn and expand its financial runway.

TC BioPharm (Holdings) PLC (“TC BioPharm” or the “Company”) (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, announces today that the Company has successfully completed its Safety Cohort and received positive review from the Data Safety Monitoring Board (DSMB).

TC BioPharm PLC a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, announced that it will change its ratio of its American Depositary Shares to ordinary shares from one ADS representing one ordinary share to one ADS representing twenty ordinary shares.